These modified EVs facilitated accumulation of RBC-EVs in metastatic cancer cells, leading to potent tumor-specific CD8+ T cell immune response, which contributed to a prominent suppression of breast cancer metastasis in the lung (122). The gene discussed is CD8A; the disease is neoplasm.